P472 SACUBITRIL/VALSARTAN IMPROVES EXERCISE PERFORMANCE IN PATIENTS WITH HEART FAILURE: A DOSE–DEPENDENT EFFECT
| العنوان: | P472 SACUBITRIL/VALSARTAN IMPROVES EXERCISE PERFORMANCE IN PATIENTS WITH HEART FAILURE: A DOSE–DEPENDENT EFFECT |
|---|---|
| المؤلفون: | M Mapelli, I Mattavelli, E Salvioni, S Paolillo, C Basile, F De Martino, C Vignati, D Magrì, V Mantegazza, G Tamborini, P Agostoni |
| المصدر: | European Heart Journal Supplements. 25:D228-D228 |
| بيانات النشر: | Oxford University Press (OUP), 2023. |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Cardiology and Cardiovascular Medicine |
| الوصف: | Background Sacubitril/Valsartan therapy has become a cornerstone of heart failure with reduced ejection fraction (HFrEF) pharmacological therapy due to its positive prognostic impact. However, conflicting results have emerged on the effects of sacubitril/valsartan on exercise performance assessed by cardiopulmonary exercise test (CPET). Aim of the study: The aim of this study was to prospectively evaluate the effects of sacubitril/valsartan on prognostically significant CPET parameters in a larger population of HFrEF patients at different drug doses. Methods We prospectively enrolled HFrEF outpatients eligible to start sacubitril/valsartan according to 2016 ESC Guidelines in 3 Heart Failure Units. Patients underwent CPET at baseline (before sacubitril/valsartan treatment), after 1, 2, 3 months (respectively after a month taking the 24/26 – 49/51 – 97/103mg doses), and 6 months after the maximum tolerated dose was reached (end–study). The subjective impression of disease–related limitation was assessed using the 12–item Kansas City Cardiomyopathy Questionnaire (KCCQ). Results 113 patients were enrolled (age 64.5±9.7, 81% males). Peak oxygen intake (peakVO2) improved at each step from 15.0±4.5 mL/min/kg at baseline to 16.5±4.9 mL/min/kg at end study visit, corresponding to 61.5±16.0 and 67.9±17.4 % of predicted, respectively (p Conclusions These findings suggest that sacubitril/valsartan benefits on exercise capacity are immediately evident at the lowest dose and progressively improve as the dose increases. |
| تدمد: | 1554-2815 1520-765X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::95ff4cd44b888e9cc10fd9daed092fbb https://doi.org/10.1093/eurheartjsupp/suad111.534 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi...........95ff4cd44b888e9cc10fd9daed092fbb |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15542815 1520765X |
|---|